Correlation Between Edgewise Therapeutics and ArriVent BioPharma,
Can any of the company-specific risk be diversified away by investing in both Edgewise Therapeutics and ArriVent BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edgewise Therapeutics and ArriVent BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Edgewise Therapeutics and ArriVent BioPharma, Common, you can compare the effects of market volatilities on Edgewise Therapeutics and ArriVent BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edgewise Therapeutics with a short position of ArriVent BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edgewise Therapeutics and ArriVent BioPharma,.
Diversification Opportunities for Edgewise Therapeutics and ArriVent BioPharma,
0.67 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Edgewise and ArriVent is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and ArriVent BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ArriVent BioPharma, and Edgewise Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edgewise Therapeutics are associated (or correlated) with ArriVent BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ArriVent BioPharma, has no effect on the direction of Edgewise Therapeutics i.e., Edgewise Therapeutics and ArriVent BioPharma, go up and down completely randomly.
Pair Corralation between Edgewise Therapeutics and ArriVent BioPharma,
Given the investment horizon of 90 days Edgewise Therapeutics is expected to under-perform the ArriVent BioPharma,. But the stock apears to be less risky and, when comparing its historical volatility, Edgewise Therapeutics is 1.69 times less risky than ArriVent BioPharma,. The stock trades about -0.05 of its potential returns per unit of risk. The ArriVent BioPharma, Common is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 3,078 in ArriVent BioPharma, Common on September 2, 2024 and sell it today you would lose (82.00) from holding ArriVent BioPharma, Common or give up 2.66% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Edgewise Therapeutics vs. ArriVent BioPharma, Common
Performance |
| Timeline |
| Edgewise Therapeutics |
| ArriVent BioPharma, |
Edgewise Therapeutics and ArriVent BioPharma, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Edgewise Therapeutics and ArriVent BioPharma,
The main advantage of trading using opposite Edgewise Therapeutics and ArriVent BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edgewise Therapeutics position performs unexpectedly, ArriVent BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will offset losses from the drop in ArriVent BioPharma,'s long position.| Edgewise Therapeutics vs. Tff Pharmaceuticals | Edgewise Therapeutics vs. Eliem Therapeutics | Edgewise Therapeutics vs. Inhibrx | Edgewise Therapeutics vs. Enliven Therapeutics |
| ArriVent BioPharma, vs. Western Digital | ArriVent BioPharma, vs. BCE Inc | ArriVent BioPharma, vs. Amkor Technology | ArriVent BioPharma, vs. WiMi Hologram Cloud |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |